Last reviewed · How we verify
PEG-G-CSF
PEG-G-CSF is a pegylated granulocyte colony-stimulating factor that stimulates the bone marrow to produce and release neutrophils, reducing the duration and severity of chemotherapy-induced neutropenia.
PEG-G-CSF is a pegylated granulocyte colony-stimulating factor that stimulates the bone marrow to produce and release neutrophils, reducing the duration and severity of chemotherapy-induced neutropenia. Used for Chemotherapy-induced neutropenia in patients with non-myeloid malignancies, Reduction of duration of severe neutropenia in patients receiving myeloablative chemotherapy followed by bone marrow transplantation.
At a glance
| Generic name | PEG-G-CSF |
|---|---|
| Also known as | G-LASTA, DA-3031 |
| Sponsor | Sanofi |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) analog |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
G-CSF binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and mobilization into peripheral blood. The pegylation (attachment of polyethylene glycol) extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. This reduces the incidence of febrile neutropenia and associated infections in cancer patients receiving myelosuppressive chemotherapy.
Approved indications
- Chemotherapy-induced neutropenia in patients with non-myeloid malignancies
- Reduction of duration of severe neutropenia in patients receiving myeloablative chemotherapy followed by bone marrow transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
- Splenic rupture
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (NA)
- Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |